TIminer

TIminer performs integrative analysis of next-generation sequencing (NGS) data to characterize tumor–immune interactions for cancer immunology and immunotherapy research.

Key Features:

• Integrative immunogenomic analyses: Combines multiple immunogenomic analyses from NGS data to assess tumor–immune system relationships.
• Human Leukocyte Antigen (HLA) typing: Identifies HLA types from NGS data for patient-specific immune profiling.
• Neoantigen prediction: Predicts candidate neoantigen peptides derived from tumor variants for immunogenicity assessment.
• Characterization of immune infiltrates: Quantifies composition and abundance of immune cell populations within the tumor microenvironment.
• Quantification of tumor immunogenicity: Assesses tumor immunogenic potential to inform likelihood of eliciting immune responses.
• Automated multi-step pipeline: Integrates and automates multi-step NGS analyses to produce reproducible outputs with reduced manual intervention.

Scientific Applications:

• Personalized medicine approaches: Enables HLA typing and neoantigen prediction to support development of tailored immunotherapies.
• Research into tumor microenvironments: Provides immune infiltrate profiles to study interactions between immune cells and tumors.
• Evaluating immunotherapy efficacy: Supplies tumor immunogenicity metrics to predict and assess responses to immunotherapeutic interventions.

Methodology:

TIminer automates the integration and analysis of NGS data through a streamlined multi-step pipeline that minimizes manual intervention.